Aeglea BioTherapeutics In... (AGLE)
NASDAQ: AGLE
· Real-Time Price · USD
12.01
0.75 (6.66%)
At close: Nov 27, 2023, 10:00 PM
Aeglea BioTherapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | -886K | -886K | 688K | 886K | 1.05M | 1.23M | 1.17M | 2.33M | 5.8M | 7.03M | 20.1M | 18.74M | 15.1M | 13.7M | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -886K | -886K | 688K | 886K | 1.05M | 1.23M | 1.17M | 2.33M | 5.8M | 7.03M | 20.1M | 18.74M | 15.1M | 13.7M | n/a |
Operating Income | -165.28M | -130.05M | -277.12M | -240.54M | -215.55M | -215.97M | -79.15M | -84.78M | -86.06M | -87.6M | -71.88M | -65.65M | -67.98M | -65.81M | -80.67M |
Interest Income | 36.89M | 31.65M | 12.71M | 7.94M | 2.43M | 1.47M | 1.22M | 837K | 461K | 209K | 124K | 111K | 121K | 173K | 315K |
Pretax Income | -84.97M | -80.28M | -365.02M | -314.47M | -294.42M | -272.76M | -78M | -83.98M | -85.62M | -87.45M | -71.88M | -65.66M | -67.95M | -65.7M | -80.38M |
Net Income | -85.05M | -80.38M | -365.05M | -314.45M | -294.43M | -272.56M | -77.8M | -83.81M | -85.44M | -87.51M | -72.02M | -65.8M | -68.07M | -65.8M | -80.38M |
Selling & General & Admin | 54.01M | 50.65M | 42.8M | 37.38M | 30.95M | 29.32M | 24.93M | 28.53M | 30.76M | 30.64M | 29.79M | 27.32M | 27.04M | 25.87M | 23.74M |
Research & Development | 225.97M | 209.01M | 119.43M | 88.46M | 70.07M | 57.39M | 55.38M | 58.58M | 61.11M | 63.99M | 62.19M | 57.07M | 56.04M | 53.64M | 56.93M |
Other Expenses | n/a | n/a | -8K | -80K | -112K | -88K | -75K | -33K | -16K | -64K | -121K | -122K | -89K | -63K | -30K |
Operating Expenses | 279.98M | 259.65M | 162.23M | 125.84M | 101.03M | 86.71M | 80.31M | 87.11M | 91.87M | 94.63M | 91.98M | 84.39M | 83.08M | 79.51M | 80.67M |
Interest Expense | n/a | n/a | n/a | n/a | 410K | 698K | 698K | 698K | 288K | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 126.87M | 160.11M | 62.69M | 81.7M | 101.03M | 86.71M | 80.31M | 87.11M | 91.87M | 94.63M | 91.98M | 84.39M | 83.08M | 79.51M | 80.67M |
Income Tax Expense | -22K | -40K | -14K | -32K | 6K | -200K | -198K | -197K | -212K | 23K | 106K | 119K | 52K | -62K | -315K |
Shares Outstanding (Basic) | 346.05M | 374.39M | 50.89M | 27.59M | 4.29M | 3.82M | 3.77M | 3.82M | 3.77M | 3.29M | 2.64M | 2.64M | 2.63M | 2.63M | 2.62M |
Shares Outstanding (Diluted) | 346.05M | 374.39M | 50.89M | 27.59M | 4.29M | 3.82M | 3.77M | 3.82M | 3.77M | 3.29M | 2.64M | 2.64M | 2.63M | 2.63M | 2.62M |
EPS (Basic) | -2.72 | -11.93 | -68.9 | -72.43 | -75.95 | -71.45 | -21.45 | -25.82 | -28.64 | -31.52 | -27.33 | -25.01 | -25.99 | -25.51 | -33.02 |
EPS (Diluted) | -2.72 | -11.93 | -68.9 | -72.43 | -75.95 | -71.45 | -21.45 | -25.82 | -28.64 | -31.52 | -27.33 | -25.01 | -25.99 | -25.51 | -33.02 |
EBITDA | -86.46M | -51.23M | 42.6M | 79.19M | 104.56M | 104.54M | -77.98M | -83.21M | -84.47M | -86M | -70.26M | -64.07M | -66.45M | -64.44M | -79.47M |
EBIT | 18.88M | 541K | -177.58M | -196.46M | -214.84M | -214.65M | -77.83M | -83.39M | -85.46M | -87.6M | -71.88M | -65.65M | -67.98M | -65.81M | -80.67M |
Depreciation & Amortization | -924.41K | -964K | 540.41K | 924.41K | 1.31M | 1.75M | 1.55M | 1.57M | 1.59M | 1.6M | 1.62M | 1.58M | 1.53M | 1.37M | 1.2M |